FFS of patients with FL according to molecular response (Responders: PCR-negative status; Nonresponders: PCR-positive status), assessed in peripheral blood at different time points from the onset of therapy: (A) 3 to 5 months (P = .1), (B) 6 to 8 months (P < .02), and (C) 9 to 14 months (P < .005). In each time point, patients observed for less than that time or who relapsed before were omitted.